Erschienen in:
01.10.2017 | Editorial
FDG PET/CT in prosthetic heart valve endocarditis: There is no need to wait
verfasst von:
A. M. Scholtens, MD, R. P. J. Budde, MD, PhD, M. G. E. H. Lam, MD, PhD, H. J. Verberne, MD, PhD
Erschienen in:
Journal of Nuclear Cardiology
|
Ausgabe 5/2017
Einloggen, um Zugang zu erhalten
Excerpt
Prosthetic heart valve (PHV) endocarditis (PVE) is a relatively uncommon complication after PHV implantation with an annual incidence of 0.3%–1.0% per patient,
1 but one that carries a high degree of morbidity and mortality.
1,
2 Echocardiography is often the first imaging modality used to diagnose PVE, but has difficulty establishing the disease in as many as 30% of cases due to acoustic shadowing.
3,
4 It is no wonder that other imaging techniques have garnered increasing interest in the setting of this disease,
5 with publications on
18F-fluorodeoxyglucose (FDG) positron emission tomography with CT attenuation correction (PET/CT) in the setting of endocarditis steadily increasing in recent years: from none before the year 1995 to 46 in the year 2016 alone. …
